DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2008/0234237 A1 MADDAFORD Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2008/0234237 A1 MADDAFORD Et Al US 20080234237A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0234237 A1 MADDAFORD et al. (43) Pub. Date: Sep. 25, 2008 (54) QUINOLONE AND Related U.S. Application Data TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY (60) Provisional application No. 60/896,829, filed on Mar. ACTIVITY 23, 2007. (76) Inventors: Shawn MADDAFORD, Publication Classification Mississauga (CA); Jailall (51) Int. Cl. RAMNAUTH, Brampton (CA); A613/60 (2006.01) Suman RAKHIT, Mississauga C07D 409/4 (2006.01) (CA); Joanne PATMAN, A 6LX 3L/24709 (2006.01) Mississauga (CA); Subhash C. A6IP 25/06 (2006.01) ANNEDI, Mississauga (CA); John C07D 409/2 (2006.01) ANDREWS, Mississauga (CA): A6II 3/55 (2006.01) Peter DOVE, Toronto (CA); Sarah (52) U.S. Cl. ... 514/165; 54.6/158: 514/312: 514/212.07; SILVERMAN, Toronto (CA); Paul 540,523 Renton, Toronto (CA) (57) ABSTRACT Correspondence Address: CLARK & ELBNG LLP The present invention features quinolones, tetrahydroquino 101 FEDERAL STREET lines, and related compounds that inhibit nitric oxide synthase BOSTON, MA 02110 (US) (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS (21) Appl. No.: 12/054,083 isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can (22) Filed: Mar. 24, 2008 be used for treating or preventing various medical conditions. Standard Test Method for the Chung SNL Model of Thermal Hyperalgesia t = -7~-14 days to -30 II.in to 0 t 30, 60,90 & 120 min. - Baseline therinal paw Re-baseline Compound testing of therinal paw withdrawal, then L5/L6 thermal paw administration withdrawal using IR box as nerve ligation operation withdrawal by the i.p. (or radiant heat source p.o.)route Patent Application Publication Sep. 25, 2008 Sheet 1 of 16 US 2008/0234237 A1 Figure 1. Standard Test Method for the Chung SNL Model of Thermal Hyperalgesia t = -7- -14 days tri -30 min time O t =30, 60,90 & 120 min. Baseline thermal paw Re-baseline Compound testing of therinal paw withdrawal, then L5/L6 the Inal paw administration withdrawal using IR box as nerve ligation operation withdrawal by the i.p. (or radiant heat source p.o.)route Figure 2. Dose response relationship for i.p. injection of Compound 11 of the invention after 30 and 60 minutes of dosing in the Chung Model of neuropathic pain. 100 80 3. 60 s O. Ch C E 40 s -O-30 minutes SS As = 4.81 (2.79 to 8.31) mg/kg, i.p. 20 -- 60 minutes As = 10.9 (8.07 to 14.8) mg/kg, i.p. 3. O 30 Dose (mg/kg, i.p.) Patent Application Publication Sep. 25, 2008 Sheet 2 of 16 US 2008/0234237 A1 Figure 3. Response of Compound of Example 3 in Chung Model Compound 3 (30 mg/kg, i.p.) Does Not Attenuate Thermal Hyperalgesia of the Hindpaw in Rats with SNL 25 -8- Distilled water -- Compound 3 1 o 5 Baseline SNL 3. 6C 2 Time (minutes) after injection Patent Application Publication Sep. 25, 2008 Sheet 3 of 16 US 2008/0234237 A1 Figure 4. Antihyperalgesia Response of Compound from Example 23 in Chung Model after i.p. dosing at 30 mg/kg. Antihyperalgesia Effects of Example 23 in the L5L6 SNL SD Rats H ; 2O 15 - g 10 5 s i o f BL post-SNL 30 60 90 120 Time (min) Patent Application Publication Sep. 25, 2008 Sheet 4 of 16 US 2008/0234237 A1 Figure 5. Standard Test Method for the Chung (SNL) Model of Tactile Hypersensitivity = -7- -14 days t = -30 min ta 0 min t = 30, 60,90 & 120 min Baseline tactile Re-baseline Compound testing of tactile allodynia using allodynia, then tactile allodynia L5/L6 nerve ligation administration by the calibrated von Frey filaments operation i.p. (or p.o.) route Patent Application Publication Sep. 25, 2008 Sheet 5 of 16 US 2008/0234237 A1 Figure 6. Antiallodynic Response of Compound from Example 23 in Chung Model after i.p. dosing at 30 mg/kg. Antiallodynic Effects of Example 23 in the L5L6 SNL SD RafS 1 5 -- 30 mg kg, i.p. 1 2 9 6 3 O BL post SNL 3. 6 9 12 Time (min) Patent Application Publication Sep. 25, 2008 Sheet 6 of 16 US 2008/0234237 A1 Figure 7. Method for the Porreca Model of Tactile Hypersensitivity t = -30 mins t = -15 mins t = 0 Hr t = 1,2,3,4,5,6 Hrs Baseline paw Compound (30 mg/kg) or vehicle p.o. Inflammatory Repeat paw withdrawal withdrawal. injection Inediator onto the theasurementS. dura (1X in 10 mL) Patent Application Publication Sep. 25, 2008 Sheet 7 of 16 US 2008/0234237 A1 Figure 8. Antiallodynic Response of Compound from Example 23 in a Migraine Model after i.p. dosing at 30 mg/kg Administered 15 Minutes Prior to Inflammatory Soup (Dural Stimulation). Example 23 (30mg/kg, p.o.) Produces Attenuation of Tactile Hyperesthesia of the Hindpaw in Rats with Inflammation of the Dura. -- Example 2330 mg/kg, p.o. (&-15 min --Wehicle, p.o. &-15 min BL h 2h 3. 4h 5 6h Time after dural stimulation Patent Application Publication Sep. 25, 2008 Sheet 8 of 16 US 2008/0234237 A1 Figure 9. Antiahyperalgesic Response of Compound from Example 37 in Chung Model after i.p. dosing at 30 mg/kg. Antihyperalgesia Effects of Example 37 in the L5L6 SNL SD Rats -i-30 mg/kg, i.p. 1 O 5 O BL post-SNL 30 60 90 120 Time (min) Patent Application Publication Sep. 25, 2008 Sheet 9 of 16 US 2008/0234237 A1 Figure 10. Antiallodynic Response of Compound from Example 47 in Chung Model after i.p. dosing at 30 mg/kg. Antihyperalgesia Effects of Example 47 in the L56 SNL S Rats 3 O - -30 mg/kg, i.p. 2 5 2 O s O 5 BL post-SNL 30 SO 90 12 Time (min) Patent Application Publication Sep. 25, 2008 Sheet 10 of 16 US 2008/0234237 A1 Figure 11. Antiallodynic Response of Compound from Example 54 in Chung Model after i.p. dosing at 30 mg/kg. Antihyperalgesia Effects of Example 54 in the 56 SN SD Rats 3 O -- 30 mgkg, i.p. O5O5 5 O B L post-SNL 30 SO 90 120 150 18O Time (min) Patent Application Publication Sep. 25, 2008 Sheet 11 of 16 US 2008/0234237 A1 Figure 12. Antihyperalgesic Response of Compound from Example 28 in the Chung (SNL) Model of Neuropathic Pain after i.p. dosing at 30 mg/kg. Antihyperalgesia Effects of Example 28 in the L5L6 SNSD Rats 3 O -di-30 mg/kg, i.p. 2 5 2 O 1 5 1 O 5 O BL post-SNL 30 SO 90 120 Time (min) Patent Application Publication Sep. 25, 2008 Sheet 12 of 16 US 2008/0234237 A1 Figure 13. Antiallodynic Response of Compound from Example 28 in a Migraine Model after p.o. Dosing at 30 mg/kg Administered 15 Minutes Prior to Inflammatory Soup (Dural Stimulation). Example 28 (30mg/kg, p.o.) Produces Attenuation of Tactile Hyperesthesia of the Hindpaw in Rats with Inflammation of the Dura (p value = 0.01; 2 Factor ANOVA). S 15 O 12 3 s 9 s s - 6 S s 3 -H Example 28 30 mg/kg, p.o. (Q-15 min -- Vehicle, p.o. (Q-15 min BL 1h 2h 3h 4h 5h 6h Time after dural stimulation Patent Application Publication Sep. 25, 2008 Sheet 13 of 16 US 2008/0234237 A1 Figure 14. Antiallodynic Response of Compound from Example 11 in the Sciatic Nerve Cuff Model of Neuropathic Pain after a single dose at 30 mg/kg (i.p.). Effect of Single Dose Example 11 on Mechanical Threshold in Rats with Sciatic Nerve cuff (n=6) 1 O. -2 pre C s 7 8 se 2rs 24, rs 11 Days After Cuff limplantation Figure 15. Antiallodynic Response of Compound from Example 11 in the Sciatic Nerve Cuff Model of Neuropathic Pain after i.p. dosing at 30 mg/kg. Effect of Four Doses of Example 11 on Mechanical Threshold in Rats with Sciatic Nerve Cuff (n=4) sy . as reusasau awaa wa was a raw was a rewr as www.eas a law awe-a- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -a- 7 5 A 2.5 A ours Hots s ots -2 Baseline 2s 27 Pre28 2. 4 Pre29 2 4h Pre3O 2 4 Pre31 2 4 32 Days After Cuff Implantation Patent Application Publication Sep. 25, 2008 Sheet 14 of 16 US 2008/0234237 A1 Figure 16. Effect of Administration of Example 11 on the frequency of paw lifts on a cold platform in the rat sciatic cuff model of neuropathic pain. Frequency of Paw Lifts on Cold Platform After 4 doses of Example 11 25 112O5O 5 O NPB NPB2 Post 4 doses Naive Neuropathic Pre & Post Figure 17. Effect of Administration of Example 11 (i.p. 30 mg/kg) hind leg weight distribution in the rat sciatic cuff model of neuropathic pain. Effect of Example 11 on Hindleg Weight Bearing in Rats with Sciatic Nerve Cuff (n=6) 2 5 1 5 Patent Application Publication Sep. 25, 2008 Sheet 15 of 16 US 2008/0234237 A1 Figure 18. Standard Test Method for the Visceral Pain Model of Tactile Hypersensitivity to -30 tie 0 to day 6 to-0 two 1.2.3, 4 Hrs Baseline Sodium butyrate twice daily for Baseline lower Compound Repeat Tactile lower back 3 days in to the colon back threshold injection Allodynia threshold Measurements Patent Application Publication Sep.
Load more

Recommended publications
  • Predictive Value of Parkinsonian Primates in Pharmacological Studies, a Comparison Between the Macaque, Marmoset and Squirrel Monkey I
    Downloaded from jpet.aspetjournals.org at ASPET Journals on October 1, 2021 NV PH JPET #247171 i HA,PH 1 Adjia Hamadjida, Philippe Huot Adjia Philippe Hamadjida, , JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward.
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest Et A1
    US007964607B2 (12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest et a1. (45) Date of Patent: Jun. 21, 2011 (54) PYRAZOLO[3,4-D]PYRIMIDINE FOREIGN PATENT DOCUMENTS COMPOUNDS EP 1460077 9/2004 WO 02085904 10/2002 (75) Inventors: Patrick Robert Verhoest, Old Lyme, CT WO 2004037176 5/2004 (US); Caroline ProulX-Lafrance, Ledyard, CT (US) OTHER PUBLICATIONS Wunder et a1, M01. PharmacoL, v01. 28, N0. 6, (2005), pp. 1776 (73) Assignee: P?zer Inc., New York, NY (U S) 1781. van der Staay et a1, Neuropharmacology, v01. 55 (2008), pp. 908 ( * ) Notice: Subject to any disclaimer, the term of this 918. patent is extended or adjusted under 35 USC 154(b) by 562 days. Primary Examiner * Susanna Moore (74) Attorney, Agent, or Firm * Jennifer A. Kispert; (21) Appl.No.: 12/118,062 Michael Herman (22) Filed: May 9, 2008 (57) ABSTRACT (65) Prior Publication Data The invention provides PDE9-inhibiting compounds of For US 2009/0030003 A1 Jan. 29, 2009 mula (I), Related US. Application Data (60) Provisional application No. 60/917,333, ?led on May 11, 2007. (51) Int. Cl. C07D 48 7/04 (2006.01) A61K 31/519 (2006.01) A61P 25/28 (2006.01) (52) US. Cl. ................................... .. 514/262.1; 544/262 (58) Field of Classi?cation Search ................ .. 544/262; 5 1 4/2 62 .1 See application ?le for complete search history. and pharmaceutically acceptable salts thereof, Wherein R, R1, (56) References Cited R2 and R3 are as de?ned herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in U.S.
    [Show full text]
  • Structure￢ﾀﾓactivity Relationship Study at C9 Position of Kaitocephalin
    Bioorganic & Medicinal Chemistry Letters 26 (2016) 3543–3546 Contents lists available at ScienceDirect Bioorganic & Medicinal Chemistry Letters journal homepage: www.elsevier.com/locate/bmcl Structure–activity relationship study at C9 position of kaitocephalin Yoko Yasuno a, Makoto Hamada a, Yuya Yoshida a, Keiko Shimamoto b, Yasushi Shigeri c, ⇑ Toshifumi Akizawa d, Motomi Konishi d, Yasufumi Ohfune a, Tetsuro Shinada a, a Graduate School of Science, Osaka City University, 3-3-138, Sugimoto, Sumiyoshi, Osaka 558-8585, Japan b Bioorganic Research Institute, Suntory Foundation for Life Sciences, 8-1-1, Seikadai, Seika-cho, Soraku-gun, Kyoto 619-0284, Japan c National Institute of Advanced Industrial Science and Technology, 1-8-31, Midorigaoka, Ikeda, Osaka 563-8577, Japan d Analytical Chemistry, Pharmaceutical Science, Setsunan University, 45-1 Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan article info abstract Article history: Kaitocephalin (KCP) isolated from Eupenicillium shearii PF1191 is an unusual amino acid natural product Received 17 May 2016 in which serine, proline, and alanine moieties are liked with carbon–carbon bonds. KCP exhibits potent Revised 8 June 2016 and selective binding affinity for one of the ionotropic glutamate receptor subtypes, NMDA receptors Accepted 9 June 2016 (K = 7.8 nM). In this study, new structure–activity relationship studies at C9 of KCP were implemented. Available online 11 June 2016 i Eleven new KCP analogs with different substituents at C9 were prepared and employed for binding affin- ity tests using native ionotropic glutamate receptors. Replacement of the 3,5-dichloro-4-hydroxybenzoyl Keywords: group of KCP with a 3-phenylpropionyl group resulted in significant loss of binding affinity for NMDARs Ionotropic glutamate receptors (K = 1300 nM), indicating an indispensable role of the aromatic ring of KCP in the potent and selective Kaitocephalin i Natural product binding to NMDARs.
    [Show full text]
  • United States Patent (10 ) Patent No.: US 10,660,887 B2 Javitt (45 ) Date of Patent: *May 26 , 2020
    US010660887B2 United States Patent (10 ) Patent No.: US 10,660,887 B2 Javitt (45 ) Date of Patent : *May 26 , 2020 (54 ) COMPOSITION AND METHOD FOR (56 ) References Cited TREATMENT OF DEPRESSION AND PSYCHOSIS IN HUMANS U.S. PATENT DOCUMENTS 6,228,875 B1 5/2001 Tsai et al. ( 71 ) Applicant : Glytech , LLC , Ft. Lee , NJ (US ) 2004/0157926 A1 * 8/2004 Heresco - Levy A61K 31/198 514/561 (72 ) Inventor: Daniel C. Javitt , Ft. Lee , NJ (US ) 2005/0261340 Al 11/2005 Weiner 2006/0204486 Al 9/2006 Pyke et al . 2008/0194631 Al 8/2008 Trovero et al. ( 73 ) Assignee : GLYTECH , LLC , Ft. Lee , NJ (US ) 2008/0194698 A1 8/2008 Hermanussen et al . 2010/0069399 A1 * 3/2010 Gant CO7D 401/12 ( * ) Notice : Subject to any disclaimer, the term of this 514 / 253.07 patent is extended or adjusted under 35 2010/0216805 Al 8/2010 Barlow 2011/0207776 Al 8/2011 Buntinx U.S.C. 154 ( b ) by 95 days . 2011/0237602 A1 9/2011 Meltzer This patent is subject to a terminal dis 2011/0306586 Al 12/2011 Khan claimer . 2012/0041026 A1 2/2012 Waizumi ( 21 ) Appl. No.: 15 /650,912 FOREIGN PATENT DOCUMENTS CN 101090721 12/2007 ( 22 ) Filed : Jul. 16 , 17 KR 2007 0017136 2/2007 WO 2005/065308 7/2005 (65 ) Prior Publication Data WO 2005/079756 9/2005 WO 2011044089 4/2011 US 2017/0312275 A1 Nov. 2 , 2017 WO 2012/104852 8/2012 WO 2005/000216 9/2013 WO 2013138322 9/2013 Related U.S. Application Data (63 ) Continuation of application No.
    [Show full text]
  • Comprehensive Review on the Interaction Between Natural Compounds and Brain Receptors: Benefits and Toxicity
    European Journal of Medicinal Chemistry 174 (2019) 87e115 Contents lists available at ScienceDirect European Journal of Medicinal Chemistry journal homepage: http://www.elsevier.com/locate/ejmech Review article Comprehensive review on the interaction between natural compounds and brain receptors: Benefits and toxicity * Ana R. Silva a, Clara Grosso b, , Cristina Delerue-Matos b,Joao~ M. Rocha a, c a Centre of Molecular and Environmental Biology (CBMA), Department of Biology (DB), University of Minho (UM), Campus Gualtar, P-4710-057, Braga, Portugal b REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Politecnico do Porto, Rua Dr. Antonio Bernardino de Almeida, 431, P-4249-015, Porto, Portugal c REQUIMTE/LAQV, Grupo de investigaçao~ de Química Organica^ Aplicada (QUINOA), Laboratorio de polifenois alimentares, Departamento de Química e Bioquímica (DQB), Faculdade de Ci^encias da Universidade do Porto (FCUP), Rua do Campo Alegre, s/n, P-4169-007, Porto, Portugal article info abstract Article history: Given their therapeutic activity, natural products have been used in traditional medicines throughout the Received 6 December 2018 centuries. The growing interest of the scientific community in phytopharmaceuticals, and more recently Received in revised form in marine products, has resulted in a significant number of research efforts towards understanding their 10 April 2019 effect in the treatment of neurodegenerative diseases, such as Alzheimer's (AD), Parkinson (PD) and Accepted 11 April 2019 Huntington (HD). Several studies have shown that many of the primary and secondary metabolites of Available online 17 April 2019 plants, marine organisms and others, have high affinities for various brain receptors and may play a crucial role in the treatment of diseases affecting the central nervous system (CNS) in mammalians.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • New Use of Glutaminyl Cyclase Inhibitors
    (19) TZZ _Z T (11) EP 2 481 408 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 01.08.2012 Bulletin 2012/31 A61K 31/4164 (2006.01) A61K 31/4184 (2006.01) A61K 31/422 (2006.01) A61K 31/4178 (2006.01) (2006.01) (2006.01) (21) Application number: 11192085.6 A61K 31/433 A61K 31/5415 A61K 31/517 (2006.01) A61P 25/28 (2006.01) (2006.01) (2006.01) (22) Date of filing: 28.02.2008 A61P 29/00 A61P 3/08 A61K 45/06 (2006.01) (84) Designated Contracting States: • Hoffmann, Torsten AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 06114 Halle / Saale (DE) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT • Cynis, Holger RO SE SI SK TR 06110 Halle / Saale (DE) • Demuth, Hans-Ulrich (30) Priority: 01.03.2007 US 892265 P 06120 Halle / Saale (DE) 14.03.2007 US 685881 (74) Representative: Hoffmann, Matthias et al (62) Document number(s) of the earlier application(s) in Maikowski & Ninnemann accordance with Art. 76 EPC: Patentanwälte 08717208.6 / 2 117 540 Kurfürstendamm 54-55 10707 Berlin (DE) (71) Applicant: Probiodrug AG 06120 Halle/Saale (DE) Remarks: This application was filed on 06-12-2011 as a (72) Inventors: divisional application to the application mentioned • Schilling, Stephan under INID code 62. 06130 Halle / Saale (DE) (54) New use of glutaminyl cyclase inhibitors (57) The present invention relates in general to an c. fibrosis, e.g. lung fibrosis, liver fibrosis, renal fibrosis, inhibitor of a glutaminyl peptide cyclotransferase, and d.
    [Show full text]
  • Pharmacology of a Novel Biased Allosteric Modulator for NMDA Receptors
    Pharmacology of a Novel Biased Allosteric Modulator for NMDA Receptors Lina Kwapisz Thesis submitted to the faculty of the Virginia Polytechnic Institute and State University in partial fulfillment of the requirements for the degree of Master of Science In Biomedical and Veterinary Sciences B. Costa, Co-Chair B. Klein M. Theus C. Reilly April 28th of 2021 Blacksburg, VA Keywords: NMDAR, allosteric modulation, CNS4, glutamate Pharmacology of a Novel Biased Allosteric Modulator for NMDA Receptors Lina Kwapisz ABSTRACT NMDA glutamate receptor is a ligand-gated ion channel that mediates a major component of excitatory neurotransmission in the central nervous system (CNS). NMDA receptors are activated by simultaneous binding of two different agonists, glutamate and glycine/ D- serine1. With aging, glutamate concentration gets altered, giving rise to glutamate toxicity that contributes to age-related pathologies like Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and dementia88,95. Some treatments for these conditions include NMDA receptor blockers like memantine130. However, when completely blocking the receptors, there is a restriction of the receptor’s normal physiological function59. A different approach to regulate NMDAR receptors is thorough allosteric modulators that could allow cell type or circuit-specific modulation, due to widely distributed GluN2 expression, without global NMDAR overactivation59,65,122. In one study, we hypothesized that the compound CNS4 selectively modulates NMDA diheteromeric receptors (GluN2A, GluN2B, GuN2C, and GluN2C) based on (three) different glutamate concentrations. Electrophysiological recordings carried out on recombinant NMDA receptors expressed in xenopus oocytes revealed that 30μM and 100μM of CNS4 potentiated ionic currents for the GluN2C and GluN2D subunits with 0.3μM Glu/100μM Gly.
    [Show full text]
  • WO 2011/089216 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date t 28 July 2011 (28.07.2011) WO 2011/089216 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 47/48 (2006.01) C07K 1/13 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 1/1 07 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) Number: International Application DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/050821 HN, HR, HU, ID, J , IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 2 1 January 201 1 (21 .01 .201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1015 1465. 1 22 January 2010 (22.01 .2010) EP kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): AS- ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, CENDIS PHARMA AS [DK/DK]; Tuborg Boulevard TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 12, DK-2900 Hellerup (DK).
    [Show full text]
  • Natural Compounds and Neuroprotection: Mechanisms of Action and Novel Delivery Systems ELENI BAGLI 1,2 , ANNA GOUSSIA 3, MARILITA M
    in vivo 30 : 535-548 (2016) Review Natural Compounds and Neuroprotection: Mechanisms of Action and Novel Delivery Systems ELENI BAGLI 1,2 , ANNA GOUSSIA 3, MARILITA M. MOSCHOS 4, NIKI AGNANTIS 3 and GEORGIOS KITSOS 2 1Institute of Molecular Biology and Biotechnology - FORTH, Division of Biomedical Research, Ioannina, Greece; 2Department of Ophthalmology, University of Ioannina, Ioannina, Greece; 3Department of Pathology, University of Ioannina, Ioannina, Greece; 4Department of Ophthalmology, University of Athens, Athens, Greece Abstract. Neurodegeneration characterizes pathologic pathological events, including oxidative stress, mitochondrial conditions, ranging from Alzheimer’s disease to glaucoma, dysfunction, inflammation and protein aggregation (2, 3). with devastating social and economic effects. It is a The increasing knowledge of the cellular and molecular complex process implicating a series of molecular and events underlying the degenerative process has greatly cellular events, such as oxidative stress, mitochondrial stimulated research for identifying compounds capable of dysfunction, protein misfolding, excitotoxicity and stopping or, at least, slowing the progress of neural inflammation. Natural compounds, because of their broad deterioration. spectrum of pharmacological and biological activities, Natural compounds are complex chemical multiple-target could be possible candidates for the management of such molecules found mainly in plants and microorganisms (4). multifactorial morbidities. However, their therapeutic These agents
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0157420 A1 Schneider (43) Pub
    US 2012O157420A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0157420 A1 Schneider (43) Pub. Date: Jun. 21, 2012 (54) TREATMENT AND PREVENTION OF A 6LX 3L/505 (2006.01) SECONDARY INTURY AFTER TRAUMA OR A6IP 29/00 (2006.01) DAMAGE TO THE CENTRAL NERVOUS A6II 3/47 (2006.01) SYSTEM A6IP 25/00 (2006.01) A6IP3/06 (2006.01) (76) Inventor: Eric B Schneider, Glen Arm, MD A6IP 9/00 (2006.01) (US) A6IP 25/22 (2006.01) A6IP 25/24 (2006.01) (21) Appl. No.: 13/392,371 A63L/366 (2006.01) A6II 3/40 (2006.01) (22) PCT Filed: Aug. 31, 2010 (52) U.S. Cl. ......... 514/171; 514/460, 514/419:514/510; (86). PCT No.: PCT/US 10/472O6 514/277; 514/275: 514/423: 514/311 S371 (c)(1), (57) ABSTRACT (2), (4) Date: Feb. 24, 2012 A method of administering one or multiple medications to human patients with CNS injury through oral or parenteral Related U.S. Application Data (including transdermal, intravenous, Subcutaneous, intra (60) Provisional application No. 61/238,453, filed on Aug. muscular) routes. Inflammatory and immunological pro 31, 2009. cesses have been shown to cause secondary damage to CNS s tissues in individuals with acute CNS injury. The present O O invention administers one or more of the following medica Publication Classification tions, which have properties that mitigate the inflammatory (51) Int. Cl. and immunological processes that lead to secondary CNS A6 IK3I/56 (2006.01) damage, via trans-dermal absorption: a statin compound A6 IK 3/405 (2006.01) (e.g., a HMG-CoA reductase inhibitor), a progesterone com A6 IK 3L/25 (2006.01) pound, or a cholinesterase inhibiting compound, among oth A6 IK 3/448 (2006.01) ers, either alone or in combination with other compounds.
    [Show full text]
  • Supplemental Figure
    ● Agonist ● Antagonist ● Interference AR AUC 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 17beta−Trenbolone 5alpha−Dihydrotestosterone 17−Methyltestosterone Testosterone propionate Norethindrone Norgestrel GSK232420A 4−Androstene−3,17−dione Progesterone 17beta−Estradiol Mifepristone 17alpha−Ethinylestradiol Hydroxyflutamide 17alpha−Hydroxyprogesterone Corticosterone Nilutamide Basic Blue 7 Triphenyltin hydroxide Bicalutamide Tributyltin benzoate 17alpha−Estradiol Gentian Violet Equilin Zinc pyrithione Triticonazole Fenitrothion Mestranol Tributyltin methacrylate 2,2−Bis(4−hydroxyphenyl)−1,1,1 Dibutyltin dichloride Flutamide Methyltrioctylammonium chlorid Rhodamine 6G Tributyltetradecylphosphonium Emamectin benzoate Phenylmercuric acetate Cyproterone acetate Chlorothalonil 9−Phenanthrol 2,2',4,4'−Tetrahydroxybenzophe Melengestrol acetate Dehydroepiandrosterone 1−Chloro−2,4−dinitrobenzene SSR240612 Methylbenzethonium chloride Vinclozolin Tetraconazole Ziram Didecyldimethylammonium chlori Econazole nitrate Myristyltrimethylammonium chlo Clorophene Abamectin Octyl gallate 2−Chloro−4−phenylphenol Bisphenol A Propanil Dexamethasone sodium phosphate meso−Hexestrol Dichlorophen Hydroxyprogesterone caproate SSR241586 Bisphenol AF Prednisone Dichlone Reserpine Chlorobenzilate Diethylstilbestrol 3−Hydroxyfluorene Procymidone 4−Cumylphenol 4−Hydroxytamoxifen Napropamide PharmaGSID_48519 Clomiphene citrate (1:1) Chlorhexidine diacetate Tebuconazole Imazalil Dinocap PharmaGSID_48513 Linuron Prochloraz Zoxamide TDCPP Captan 3,3'−Dimethoxybenzidine dihydr 4−Phenylphenol
    [Show full text]